• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness Clinical Sciences
Conclusions—The usual Japanese dose of pravastatin significantly reduced the progression of carotid IMT at 5 years in patients with noncardioembolic stroke.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00361530.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Masatoshi Koga, Kazunori Toyoda, Kazuo Minematsu, Masahiro Yasaka, Yoji Nagai, Shiro Aoki, Tomohisa Nezu, Naohisa Hosomi, Tatsuo Kagimura, Hideki Origasa, Kenji Kamiyama, Rieko Suzuki, Toshiho Ohtsuki, Hirofumi Maruyama, Kazuo Kitagawa, Shinichiro Uchiyam Tags: Risk Factors, Secondary Prevention, Ultrasound, Atherosclerosis Original Contributions Source Type: research

Extravascular Optical Coherence Tomography: Evaluation of Carotid Atherosclerosis and Pravastatin Therapy Basic Sciences
Conclusions— OCT imaging offers the potential for real-time, detailed vessel lumen evaluation, potentially improving surgical accuracy and outcomes during cerebrovascular neurosurgical procedures. Pravastatin significantly increases vessel lumen patency in the ApoE–/– mouse on HFD.
Source: Stroke - March 24, 2014 Category: Neurology Authors: Wicks, R. T., Huang, Y., Zhang, K., Zhao, M., Tyler, B. M., Suk, I., Hwang, L., Ruzevick, J., Jallo, G., Brem, H., Pradilla, G., Kang, J. U. Tags: Imaging, Coronary imaging: angiography/ultrasound/Doppler/CC, Other diagnostic testing, Computerized tomography and Magnetic Resonance Imaging Basic Sciences Source Type: research

Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and ...
Source: Current Diabetes Reports - November 20, 2019 Category: Endocrinology Source Type: research